CD8+ T-cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes

PLoS Pathogens

Volumn 2, Issue 8, 2006, Pages 0731-0740

  Martin, Diana L ^a   Weatherly, D Brent ^a   Laucella, Susana A ^b   Cabinian, Melissa A ^a   Crim, Matthew T ^a   Sullivan, Susan ^a,d   Heiges, Mark ^a   Craven, Sarah H ^a   Rosenberg, Charles S ^a   Collins, Matthew H ^a   Sette, Alessandro ^c   Postan, Miriam ^b   Tarleton, Rick L ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d Louisiana State University at Alexandria   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; SIALIDASE; ISOENZYME;

ARTICLE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; HUMAN; MEDICAL RESEARCH; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; TRYPANOSOMA CRUZI; ADULT; ANIMAL; ARGENTINA; BRAZIL; C57BL MOUSE; CELL CULTURE; CYTOTOXICITY; DISEASE MODEL; ENZYMOLOGY; GENETIC VARIABILITY; GENETICS; GENOME; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX;

BACTERIA (MICROORGANISMS); PROTOZOA; TRYPANOSOMA CRUZI;

ADULT; ANIMALS; ARGENTINA; BRAZIL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHAGAS DISEASE; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENOME; HUMANS; ISOENZYMES; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; NEURAMINIDASE; TRYPANOSOMA CRUZI; VARIATION (GENETICS);

EID: 33748057802     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.0020077     Document Type: Article

References (57)

1. Wong P, Pamer EG (2003) CD8 T-cell responses to infectious pathogens. Annu Rev Immunol 21: 29-70.
2. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96.
3. Klenerman P, Cerundolo V, Dunbar PR (2002) Tracking T cells with tetramers: New tales from new tools. Nat Rev Immunol 2: 263-272.
4. + T-cell responses during microbial infection. Curr Opin Immunol 15: 436-442.
5. Lauvau G, Vijh S, Kong P, Horng T, Kerksiek K, et al. (2001) Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294: 1735-1739.
6. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4: 225-234.
7. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.
8. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8: 379-385.
9. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992-4000.
10. + CTLs are essential for protective immunity against Encephalitozoon cuniculi infection. J Immunol 162: 6086-6091.
11. + T cells as seen in immunity to malaria. Immunol Rev 201: 291-303.
12. + T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol 84: 207-212.
13. Sano G, Hafalla JC, Morrot A, Abe R, Lafaille JJ, et al. (2001) Swift development of protective effector functions in naive CD8(+) T cells against malaria liver stages. J Exp Med 194: 173-180.
14. Tarleton RL, Koller BH, Latour A, Postan M (1992) Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356: 338-340.
15. Wizel B, Garg N, Tarleton RL (1998) Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 66: 5073-5081.
16. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A 85: 573-576.
17. Sedegah M, Hedstrom R, Hobart P, Hoffman SL (1994) Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A 91: 9866-9870.
18. Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17: 51-88.
19. Chen W, Anton LC, Bennink JR, Yewdell JW (2000) Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12: 83-93.
20. + epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients. Microbes Infect 7: 688-697.
21. + CTL. J Immunol 160: 1817-1823.
22. Katae M, Miyahira Y, Takeda K, Matsuda H, Yagita H, et al. (2002) Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect Immun 70: 4833-4840.
23. + cytotoxic T lymphocytes target Trypanosoma cruzi-infected host cells. Parasite Immunol 24: 401-412.
24. Rodrigues MM, Boscardin SB, Vasconcelos JR, Hiyane MI, Salay G, et al. (2003) Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. An Acad Bras Cienc 75: 443-468.
25. Wizel B, Palmieri M, Mendoza C, Arana B, Sidney J, et al. (1998) Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. J Clin Invest 102: 1062-1071.
26. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, et al. (2004) Frequency of interferon-gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 189: 909-918.
27. Garg N, Nunes MP, Tarleton RL (1997) Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway. J Immunol 158: 3293-3302.
28. Atwood JA 3rd, Weatherly DB, Minning TA, Bundy B, Cavola C, et al. (2005) The Trypanosoma cruzi proteome. Science 309: 473-476.
29. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409-415.
30. Masopust D, Vezys V, Marzo AL, Lefrancois L (2001) Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413-2417.
31. + T cells in vivo during infection and tumor rejection. J Immunol 163: 3369-3378.
32. + T cell responses in the regression of retrovirus-induced sarcomas. J Immunol 169: 3191-3199.
33. +-T-cell expansion and trafficking following central nervous system infection. J Virol 77: 2775-2778.
34. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, et al. (1998) Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 8: 177-187.
35. Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol 2: 251-262.
36. Campetella O, Sanchez D, Cazzulo JJ, Frasch AC (1992) A superfamily of Trypanosoma cruzi surface antigens. Parasitol Today 8: 378-381.
37. Doherty PC, Christensen JP (2000) Accessing complexity: The dynamics of virus-specific T cell responses. Annu Rev Immunol 18: 561-592.
38. + T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun 69: 5477-5486.
39. Minoprio PM, Coutinho A, Joskowicz M, D'Imperio Lima MR, Eisen H (1986) Polyclonal lymphocyte responses to murine Trypanosoma cruzi infection. II. Cytotoxic T lymphocytes. Scand J Immunol 24: 669-679.
40. Minoprio P, Itohara S, Heusser C, Tonegawa S, Coutinho A (1989) Immunobiology of murine T. cruzi infection: The predominance of parasite-nonspecific responses and the activation of TCRI T cells. Immunol Rev 112: 183-207.
41. + T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci U S A 103: 994-999.
42. Tomlinson S, Pontes de Carvalho LC, Vandekerckhove F, Nussenzweig V (1994) Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. J Immunol 153: 3141-3147.
43. Chuenkova M, Pereira ME (1995) Trypanosoma cruzi trans-sialidase: Enhancement of virulence in a murine model of Chagas' disease. J Exp Med 181: 1693-1703.
44. Pereira-Chioccola VL, Schenkman S (1999) Biological role of Trypanosoma cruzi trans-sialidase. Biochem Soc Trans 27: 516-518.
45. Belen Carrillo M, Gao W, Herrera M, Alroy J, Moore JB, et al. (2000) Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence. Infect Immun 68: 2728-2734.
46. Frasch AC (2000) Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol Today 16: 282-286.
47. El-Sayed NM, Myler PJ, Blandin G, Berriman M, Crabtree J, et al. (2005) Comparative genomics of trypanosomatid parasitic protozoa. Science 309: 404-409.
48. Tarleton RL, Kissinger J (2001) Parasite genomics: Current status and future prospects. Curr Opin Immunol 13: 395-402.
49. Plebanski M, Lee EA, Hannan CM, Flanagan KL, Gilbert SC, et al. (1999) Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat Med 5: 565-571.
50. Kahn S, Van Voorhis WC, Eisen H (1990) The major 85-kD surface antigen of the mammalian form of Trypanosoma cruzi is encoded by a large heterogeneous family of simultaneously expressed genes. J Exp Med 172: 589-597.
51. + T cells in chronic Chagas' disease patients. Int Immunol 18: 465-471.
52. Zhang L, Tarleton RL (1999) Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 180: 480-486.
53. Gulukota K, Sidney J, Sette A, DeLisi C (1997) Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol 267: 1258-1267.
54. Martin DL, Tarleton RL (2005) Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol 174: 1594-1601.
55. Parham P, Brodsky FM (1981) Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3: 277-299.
56. Barber DL, Wherry EJ, Ahmed R (2003) Cutting edge: Rapid in vivo killing by memory CD8 T cells. J Immunol 171: 27-31.
57. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31: 3497-3500.